Empyrean Neuroscience

About:

Empyrean is using genetic engineering to treat severe neuropsychiatric and neurologic illnesses in a way that will revolutionize healthcare.

Website: https://empyrean.bio/

Twitter/X: Empyrean_bio

Top Investors: Spore Partners

Description:

Empyrean is using genetic engineering to treat severe neuropsychiatric and neurologic illnesses in a way that will revolutionize healthcare.

Total Funding Amount:

$22M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

New York, New York, United States

Founded Date:

2019-01-01

Founders:

Tom Henley

Number of Employees:

1-10

Last Funding Date:

2022-10-18

IPO Status:

Private

Industries: